Home
Products
Learn
About
Pricing
Log In
PIQ
Asset Logo

Proteomics International Laboratories Ltd

๐Ÿ‡ฆ๐Ÿ‡บ ASX

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿ”ญ LIFE SCIENCES TOOLS & SERVICES

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

+ 9.67%
Annual Growth

5 years average annual capital growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

14
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bioanalytical services. The company specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. The company focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.

๐Ÿ“ˆ Performance

Price History

+148.53%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.45

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in PIQ

14

๐Ÿ“Š Total Capital Earnings

$33K

๐Ÿ”ƒ Average investment frequency

25 weeks

๐Ÿ’ต Average investment amount

$2,721

โฐ Last time a customer invested in PIQ

9 days
PIQ investor breakdown
๐Ÿ’ต Income of investors

More than 200k

7%

150k - 200k

7%

100k - 150k

20%

50k - 100k

27%

Less than 50k

33%
๐Ÿ‘ถ Age of investors

18 - 25

21%

26 - 34

14%

35 - 90

64%
๐Ÿ™‹ Legal gender of investors

Female

36%

Male

64%

Pearlers who invest in PIQ also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

8.55%

๐Ÿ“Š Share price

$96.77 AUD

๐Ÿ‡ฆ๐Ÿ‡บ AUSTRALIA

๐Ÿงฑ MATERIALS

๐Ÿ’ธ FINANCIALS

โ›ณ๏ธ DIVERSIFIED

๐Ÿ“ˆ HIGH PRICE GROWTH

Find Out More

Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. The company develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. The company operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

๐Ÿ™Œ Performance (5Yr p.a)

409.96%

๐Ÿ“Š Share price

$25.69 AUD

๐Ÿงฌ BIOTECHNOLOGY

DroneShield Ltd. engages in the development and commercialisation of hardware and software technology for drone detection and security. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-06-22. The company provides artificial intelligence-based platforms for protection against advanced threats, such as drones and autonomous systems. The company offers customers bespoke counter-drone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime, or airborne platforms. The Companyโ€™s products include DroneGun Tactical, DroneGun MKIII, DroneSentry, DroneSentry-C2, DroneSentry-X, RfPatrol and DroneSim among others. The DroneGun Tactical is an unmanned aerial systems (UAS) countermeasure designed for two-hand operation and long-range defeat. RfPatrol is a passive/non-emitting wearable UAS detection device. The Companyโ€™s capabilities include C-UAS, C-UxS Training, and Electronic Warfare.

๐Ÿ™Œ Performance (5Yr p.a)

224.68%

๐Ÿ“Š Share price

$1.15 AUD

๐Ÿš€ AEROSPACE & DEFENSE

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

13.34%

๐Ÿ“Š Share price

$127.58 AUD

๐ŸŒ GLOBAL

๐Ÿค– TECHNOLOGY

โ›ณ๏ธ DIVERSIFIED

๐Ÿ“ˆ HIGH PRICE GROWTH

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. The company is headquartered in Perth, Western Australia. The Companyโ€™s operations include Mt Weld, Lynas Malaysia, Kalgoorlie and Lynas USA. The company focuses on developing the Mt Weld resource, which includes ongoing exploration, production of mixed rare earths concentrates, and an expansion project to increase concentrate feedstock production to support 12,000 tons per annum of finished NdPr oxide. The Lynas Malaysia advanced materials plant is located on a 100-hectare site in the Gebeng Industrial Estate, a purpose-built petrochemical industry zone near Kuantan, on the east coast of Malaysia. Its rare earths processing facility in Kalgoorlie undertakes value-added processing of rare earths. The firm's subsidiaries include Lynas Malaysia Sdn Bhd, Lynas Africa Ltd, Lynas Kalgoorlie Pty Ltd and Lynas USA LLC.

๐Ÿ™Œ Performance (5Yr p.a)

97.93%

๐Ÿ“Š Share price

$8.84 AUD

๐Ÿ•Š๏ธ SOCIALLY AWARE

โ›๏ธ MINING

Want more shares? Try these...

PIODA

๐Ÿ“Š Share price

$0.08 AUD
Compare
Add to watchlist